Efficacy trials of biomedical strategies to prevent HIV infection

Current Opinion in HIV and AIDS

Volumn 3, Issue 4, 2008, Pages 504-508

  Kaldor, John M ^a   Guy, Rebecca J ^b   Wilson, David ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BURNET INSTITUTE   (Australia)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

Chemoprophylaxis; Community engagement; HIV prevention; Microbicides; Randomized trials; Vaccines

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE; TENOFOVIR;

BEHAVIOR; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICAL RESEARCH; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; STANDARD;

EID: 67649619500     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32830413dc     Document Type: Review

References (41)

1. Grosskurth H, Gray R, Hayes R, et al. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. The Lancet 2003; 355:1981-1987.
2. Weiss HA, Halperin D, Bailey RC, et al. Male circumcision for HIV prevention: from evidence to action? AIDS 2008; 22:567-574. With the first biomedical preventive intervention now proven, this paper maps the long road ahead to implementation.
3. Merck, HIV Vaccine Trial Network. Vaccination and enrollment are discontinued in phase II trials of Merck's investigational HIV vaccine candidate. Interim analysis of STEP study shows vaccine was not effective; 21 September 2007. http://www.hivvaccineenterprise.org/-dwn/news/FINAL-HIV-Vaccine- Press-Release.pdf. [Accessed 15 April 2008]
4. VaxGen I. VaxGen announces initial results of its phase III AIDS vaccine trial; 24 February 2008. http://briandeer.com/vaxgen/aidsvax-release.htm. [Accessed 15 April 2008]
5. Council P. Trial shows anti-HIV microbicide is safe, but does not prove it effective; 18 February 2008. http://www.popcouncil.org/mediacenter/ newsreleases/Carraguard-Findings.html. [Accessed 15 April 2008]
6. Halpern V, Wang L, Obunge O, et al. Effectiveness of cellulose sulfate gel for prevention of HIV: results of the phase III trial in Nigeria [abstract]. In: Proceedings of the Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 22-25 July 2007; Sydney. Geneva: IAS; 2007. Abstract WESS302.
7. Van Damme L, Govinden R, Mirembe F, et al. Phase III trial of 6% cellulose sulfate (CS) gel for the prevention of HIV transmission [abstract]. In: Proceedings of the Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 22-25 July 2007; Sydney. Geneva: IAS; 2007. Abstract WESS301
8. Wilkinson D, Tholandi M, Ramjee G, Rutherford GW. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002; 2:613-617.
9. Padian N, van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. The Lancet 2007; 370:251-261. This describes a long awaited and important trial that was ultimately disappointing but has led to many lessons for the prevention field.
10. Celum C, Wald A, Hughes J, et al. HSV-2 suppressive therapy for prevention of HIV acquisition: results of HPTN 039 [abstract]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston. Alexandria: CROI 2008. Paper 32.
11. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of hiv infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clinical Trials 2007; 2:1-9. This is the first publication of a trial of chemoprophylaxis against HIV infection. Unfortunately the study was vastly underpowered after the closure of other sites that were supposed to ensure adequate sample size.
12. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. The Lancet 2007; 369:787-797. This is a comprehensive review of microbicide development from two leaders in the field.
13. Lagakos SW, Gable AR. Challenges to HIV prevention: seeking effective measures in the absence of a vaccine. N Engl J Med 2008; 358:1543-1545.
14. Dhawan D, Mayer KH. Microbicides to prevent HIV transmission: Overcoming obstacles to chemical barrier protection. J Infect Dis 2006; 193:36-44.
15. Bartholow BN, Buchbinder S, Celum C, et al., for the VISION/VAX004 Study Team. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. JAIDS 2005; 39:90-101.
16. Agot KE, Kiarie JN, Nguyen HQ, et al. Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 2007; 1:66-70.
17. Coplan PM, Mitchnick M, Rosenberg ZF. Public health: regulatory challenges in microbicide development. Science 2004; 304:1911-1912.
18. Fleming TR, Richardson BA. Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis 2004; 190:666-674.
19. Fleming TR, Richardson BA. Reply to Skoler et al. and to Stein and Susser. J Infect Dis 2005; 191:1378-1379.
20. Stein ZA, Susser MW. Control groups in microbicide trials: in defense of orthodoxy. J Infect Dis 2005; 191:1377-1378.
21. Foss AM, Vickerman PT, Heise L, Watts CH. Shifts in condom use following microbicide introduction: should we be concerned? AIDS 2003; 17:1227-1237.
22. Muula AS. Male circumcision to prevent HIV transmission and acquisition: what else do we need to know? AIDS Behav 2007; 11:357-363.
23. Lott JP. Module three: Vulnerable/special participant populations. Developing World Bioethics 2005; 5:30-54.
24. Nunn A, Rutterford C, Hayes R, McCormack S. Proving efficacy in microbicide trials: What design, how many women and for how long? [Poster]. In: Proceedings of the Microbicides Development Programme Workshop; 5-6 December 2006; Durban. London: MDP; 2006. PB59.
25. UNAIDS. Trends in HIV incidence and prevalence: natural course of the epidemic or results from behavioural change? Geneva: UNAIDS; 1999.
26. Karita E, Price M, Hunter E, et al. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS 2007; 21:403-408. The authors assess the validity of the most widely used HIV incidence assay, which has been criticized for potentially overestimating in the African context.
27. McDougal J, Parekh BS, Peterson ML, et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses 2006; 22:945-952.
28. Council for International Organizations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects. Geneva: Council for International Organizations of Medical Sciences; 2002. www. cioms.ch/guidelines-nov-2002-blurb.htm. [Accessed 7 March 2006]
29. World Medical Association. Ethical principles for medical research involving human subjects. Declaration of Helsinki. Ferney-Voltaire: World Medical Association; 2000. www.wma.net/e/policy/b3.htm. [Accessed 7 March 2006]
30. Forbes A. Moving toward assured access to treatment in microbicide trials. PLoS Medicine 2006; 3:980-983.
31. Page-Shafer K, Saphonn V, Sun L, et al. HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia. Lancet 2005; 366:1499-1503.
32. Bhutta Z. Standard of care should reflect local conditions and not the best western standards. BMJ 2004; 329:1114-1115.
33. Chima SC. Regulation of biomedical research in Africa. BMJ 2006; 332:848-851.
34. Anonymous. The trials of tenofovir trials. Lancet 2005; 365:1111.
35. Nagelkerke NJ, Moses S, de Vlas SJ, Bailey RC. Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa. BMC Infect Dis 2007; 13:16.
36. Ramjee G, Morar NS, Mtimkulu J, et al. Perceptions of vaginal microbicides as an HIV prevention method among healthcare providers in KwaZulu-Natal, South Africa. AIDS Research and Therapy 2007; 4:7.
37. Ramjee G, Shattock R, Delany S, et al. Microbicides 2006 conference. AIDS Res Ther 2006; 3:1-10.
38. Westercamp N, Bailey RC. Acceptability of male circumcision for prevention of HIV/AIDS in Sub-Saharan Africa: a review. AIDS Behav 2007; 11:341-355. This presents critical assessment of acceptability studies of male circumcision that tells us that the intervention is generally acceptable.
39. Mantell JE, Myer L, Carballo-Diéguez A, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med 2005; 2:19-30.
40. Ramjee G, Govinden R, Morar NS, Mbewu A. South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Medicine 2007; 4:1167-1173. An issue of increasing importance: what happens on the ground when a trial is stopped ahead of the planned completion date?
41. Duran N. Listening to consumers and HIV vaccine preparedness. Lancet 2005; 365:1119-1121.